BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tirzepatide (Zepbound) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tirzepatide (Zepbound)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07299084-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tirzepatide (Zepbound): Phase 1 readout est. (NCT07299084)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 1\, Obesity.\nStudy: A Study to 
 Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the
  Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabe
 tes Mellitus and Participants With Overweight or Obesity Without Type 2 Di
 abetes Mellitus\nEstimated primary completion: November 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07299084
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06962280-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT06962280)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: A Long-Term
  Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesi
 ty or Overweight\nEstimated primary completion: November 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06962280
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06914895-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT06914895)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: A Study of 
 Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabet
 es and Obesity or Overweight\nEstimated primary completion: November 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069
 14895
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07740291-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20261123
DTEND;VALUE=DATE:20261124
SUMMARY:Tirzepatide (Zepbound): Phase na readout est. (NCT07740291)
DESCRIPTION:Tirzepatide (Zepbound)\, phase na\, Obesity.\nStudy: Tirzepatid
 e Impact Assessment Study\nEstimated primary completion: 23 November 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077
 40291
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07803744-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tirzepatide (Zepbound): Phase 1 readout est. (NCT07803744)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 1\, Obesity.\nStudy: A Study of 
 Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and 
 Overweight or Obesity\nEstimated primary completion: December 2026. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07803744
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07373834-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tirzepatide (Zepbound): Phase na readout est. (NCT07373834)
DESCRIPTION:Tirzepatide (Zepbound)\, phase na\, Obesity.\nStudy: Tirzepatid
 e and Muscle Outcomes in Obesity\nEstimated primary completion: December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepb
 ound#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07373834
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06759701-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tirzepatide (Zepbound): Phase 1 readout est. (NCT06759701)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 1\, Obesity.\nStudy: Pre-Surgica
 l Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Interm
 ediate Risk Prostate Cancer: A Pilot Feasibility Study\nEstimated primary 
 completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/tirzepatide-zepbound#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06759701
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06802081-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT06802081)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: TIRzepatide
  for the Treatment of Obesity in Patients With Atrial Fibrillation\nEstima
 ted primary completion: 31 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06802081
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06721507-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tirzepatide (Zepbound): Phase 4 readout est. (NCT06721507)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 4\, Obesity.\nStudy: 2024 Tirzep
 atide-Bariatric Surgery\nEstimated primary completion: 31 December 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06721
 507
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07057310-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tirzepatide (Zepbound): Phase 4 readout est. (NCT07057310)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 4\, Obesity.\nStudy: Aging Well:
  Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular He
 alth in Postmenopausal Women\nEstimated primary completion: 31 December 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbo
 und#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07057310
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07364175-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Tirzepatide (Zepbound): Phase na readout est. (NCT07364175)
DESCRIPTION:Tirzepatide (Zepbound)\, phase na\, Obesity.\nStudy: A Trial Wi
 thin Cohort Feasibility Study Design Comparing Standard of Care Versus Wei
 ght Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension i
 n Young Adults\nEstimated primary completion: January 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07364175
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07154719-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Tirzepatide (Zepbound): Phase 4 readout est. (NCT07154719)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 4\, Obesity.\nStudy: GLP-1R Acti
 ons on Muscle and the Skeleton\nEstimated primary completion: 1 February 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepb
 ound#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07154719
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07481747-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270214
DTEND;VALUE=DATE:20270215
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT07481747)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: Efficacy an
 d Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are
  Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
 \nEstimated primary completion: 14 February 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07481747
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06484114-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270215
DTEND;VALUE=DATE:20270216
SUMMARY:Tirzepatide (Zepbound): Phase na readout est. (NCT06484114)
DESCRIPTION:Tirzepatide (Zepbound)\, phase na\, Obesity.\nStudy: Evaluation
  of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in 
 Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzep
 atide\nEstimated primary completion: 15 February 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06484114
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07685834-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Tirzepatide (Zepbound): Phase na readout est. (NCT07685834)
DESCRIPTION:Tirzepatide (Zepbound)\, phase na\, Obesity.\nStudy: Evaluation
  of Facial and Neck Skin Laxity With SofWave Treatment in Adults Initiatin
 g Tirzepatide for Weight Loss\nEstimated primary completion: 1 March 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076
 85834
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06606821-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270320
DTEND;VALUE=DATE:20270321
SUMMARY:Tirzepatide (Zepbound): Phase 4 readout est. (NCT06606821)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 4\, Obesity.\nStudy: The Effects
  of Tirzepatide in People With Overweight/Obesity and Coronary Artery Dise
 ase\nEstimated primary completion: 20 March 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06606821
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06811324-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT06811324)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: Effects of 
 Tirzepatide on Muscle and Vascular Health in Obese Older Adults\nEstimated
  primary completion: 1 April 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/tirzepatide-zepbound#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06811324
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07293325-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270402
DTEND;VALUE=DATE:20270403
SUMMARY:Tirzepatide (Zepbound): Phase na readout est. (NCT07293325)
DESCRIPTION:Tirzepatide (Zepbound)\, phase na\, Obesity.\nStudy: Semaglutid
 e and Tirzepatide for Genetic Aging Delay in Adults With Obesity\nEstimate
 d primary completion: 2 April 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07293325
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07463846-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270428
DTEND;VALUE=DATE:20270429
SUMMARY:Tirzepatide (Zepbound): Phase 1/2 readout est. (NCT07463846)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 1/2\, Obesity.\nStudy: A Study t
 o Evaluate ALN-2232 in Participants With Obesity\nEstimated primary comple
 tion: 28 April 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 tirzepatide-zepbound#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07463846
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06854614-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270428
DTEND;VALUE=DATE:20270429
SUMMARY:Tirzepatide (Zepbound): Phase 4 readout est. (NCT06854614)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 4\, Obesity.\nStudy: Sequential 
 Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss a
 nd MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)\
 nEstimated primary completion: 28 April 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06854614
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06191848-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Tirzepatide (Zepbound): Phase 4 readout est. (NCT06191848)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 4\, Obesity.\nStudy: Subcutaneou
 s Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis
  (STOP KNEE-OA)\nEstimated primary completion: May 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06191848
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07292519-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270515
DTEND;VALUE=DATE:20270516
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT07292519)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: Tirzepatide
  Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol
  Use Disorder (AUD) and Overweight/Obesity (OOB)\nEstimated primary comple
 tion: 15 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ti
 rzepatide-zepbound#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07292519
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07866183-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tirzepatide (Zepbound): Phase na readout est. (NCT07866183)
DESCRIPTION:Tirzepatide (Zepbound)\, phase na\, Obesity.\nStudy: Trial of I
 nnovative Fat-loss Focused Approaches in Patients With Class I Obesity: a 
 Comparative Study\nEstimated primary completion: June 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07866183
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07738276-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270611
DTEND;VALUE=DATE:20270612
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT07738276)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: Evaluation 
 of the Efficacy and Safety of Tirzepatide\, a Dual GLP-1/GIP Agonist\, on 
 Functional Capacity in Reduced Ejection Fraction Heart Failure Patients Wi
 th Obesity\nEstimated primary completion: 11 June 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07738276
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07354880-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tirzepatide (Zepbound): Phase 4 readout est. (NCT07354880)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 4\, Obesity.\nStudy: Effect of T
 irzepatide on Cardiovascular and Metabolic Parameters in Obese Adult Patie
 nts With Congenital Heart Disease\nEstimated primary completion: 30 June 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepb
 ound#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07354880
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07671391-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT07671391)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: A Randomize
 d\, Double-blind\, Placebo-controlled Study Evaluating the Effect of LAE10
 2 Injection in Combination With Tirzepatide on Body in Obese Participants\
 nEstimated primary completion: July 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07671391
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07438444-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Tirzepatide (Zepbound): Phase 4 readout est. (NCT07438444)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 4\, Obesity.\nStudy: A Study of 
 Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 
 Diabetes Mellitus or Obesity\nEstimated primary completion: July 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0743844
 4
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06803888-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Tirzepatide (Zepbound): Phase 4 readout est. (NCT06803888)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 4\, Obesity.\nStudy: Bariatric S
 urgery vs. Semaglutide vs. Tirzepatide\nEstimated primary completion: 1 Ju
 ly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-
 zepbound#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06803888
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06864026-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Tirzepatide (Zepbound): Phase 4 readout est. (NCT06864026)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 4\, Psoriatic Arthritis.\nStudy:
  A Study to Investigate Effectiveness of Tirzepatide Following Initiation 
 of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweig
 ht or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)\nEstimated prima
 ry completion: August 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/tirzepatide-zepbound#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06864026
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07588438-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:Tirzepatide (Zepbound): Phase 4 readout est. (NCT07588438)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 4\, Obesity.\nStudy: Efficacy\, 
 Safety\, and Tolerability of Tirzepatide in Real-World Conditions in Parag
 uay.\nEstimated primary completion: 10 August 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07588438
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06732245-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270815
DTEND;VALUE=DATE:20270816
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT06732245)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: Safety and 
 Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese\n
 Estimated primary completion: 15 August 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06732245
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06734273-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Tirzepatide (Zepbound): Phase 1 readout est. (NCT06734273)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 1\, Obesity.\nStudy: Randomized 
 Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight 
 Loss\nEstimated primary completion: September 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06734273
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06143956-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT06143956)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: A Master Pr
 otocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs
 ) in Adult Participants With Obesity or Overweight\nEstimated primary comp
 letion: September 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/tirzepatide-zepbound#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06143956
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06575738-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Tirzepatide (Zepbound): Phase 1 readout est. (NCT06575738)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 1\, Obesity.\nStudy: Physiologic
  Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Ad
 olescents\nEstimated primary completion: 1 September 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06575738
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07218445-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270918
DTEND;VALUE=DATE:20270919
SUMMARY:Tirzepatide (Zepbound): Phase 4 readout est. (NCT07218445)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 4\, Obesity.\nStudy: The Effect 
 of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Po
 st-menopausal Women With Obesity\nEstimated primary completion: 18 Septemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-
 zepbound#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07218445
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06518837-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT06518837)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: Tirzepatide
  for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER
 2 Negative Breast Cancer\nEstimated primary completion: 30 September 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT065
 18837
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06439277-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT06439277)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: A Study of 
 Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (
 SURMOUNT-ADOLESCENTS-2)\nEstimated primary completion: October 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06439277
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05556512-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT05556512)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: A Study of 
 Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adu
 lts With Obesity\nEstimated primary completion: October 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05556512
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07893457-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20271026
DTEND;VALUE=DATE:20271027
SUMMARY:Tirzepatide (Zepbound): Phase 4 readout est. (NCT07893457)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 4\, Obesity.\nStudy: Effects of 
 Tirzepatide on Esophagogastric Junction Mechanics\, Reflux Burden\, and Ga
 stric Physiology in Adults With Obesity\nEstimated primary completion: 26 
 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tirzepa
 tide-zepbound#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07893457
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06861439-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Tirzepatide (Zepbound): Phase 4 readout est. (NCT06861439)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 4\, Obesity.\nStudy: GLP-1s to E
 nhance Lasting Optimal Weight\nEstimated primary completion: 30 October 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbo
 und#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06861439
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07228741-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT07228741)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: Resistance 
 Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of A
 LL With Obesity\nEstimated primary completion: November 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07228741
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06751589-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tirzepatide (Zepbound): Phase 1 readout est. (NCT06751589)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 1\, Obesity.\nStudy: A Study of 
 a Weight Loss Intervention in People With Endometrial Cancer\nEstimated pr
 imary completion: December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/tirzepatide-zepbound#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06751589
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07707778-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tirzepatide (Zepbound): Phase 4 readout est. (NCT07707778)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 4\, Obesity.\nStudy: Tirzepatide
 's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppre
 ssed People With HIV\nEstimated primary completion: December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07707778
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06847399-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT06847399)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: Efficacy an
 d Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for 
 Binge-Eating Disorder\nEstimated primary completion: 1 December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06847399
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07257484-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20271203
DTEND;VALUE=DATE:20271204
SUMMARY:Tirzepatide (Zepbound): Phase 4 readout est. (NCT07257484)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 4\, Obesity.\nStudy: Tirzepatide
 's Role in Postmenopausal HR+ Breast Cancer Survivors\nEstimated primary c
 ompletion: 3 December 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/tirzepatide-zepbound#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07257484
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07382024-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tirzepatide (Zepbound): Phase na readout est. (NCT07382024)
DESCRIPTION:Tirzepatide (Zepbound)\, phase na\, Obesity.\nStudy: Tirzepatid
 e to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation\nE
 stimated primary completion: 31 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07382024
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07728318-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20280112
DTEND;VALUE=DATE:20280113
SUMMARY:Tirzepatide (Zepbound): Phase na readout est. (NCT07728318)
DESCRIPTION:Tirzepatide (Zepbound)\, phase na\, Obesity.\nStudy: Efficacy\,
  Safety\, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese T
 ype 2 Diabetic Patients\nEstimated primary completion: 12 January 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077283
 18
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06801015-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Tirzepatide (Zepbound): Phase 4 readout est. (NCT06801015)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 4\, Obesity.\nStudy: Effects of 
 Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GI
 P [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor 
 Functions\nEstimated primary completion: 31 January 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06801015
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07443956-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Tirzepatide (Zepbound): Phase na readout est. (NCT07443956)
DESCRIPTION:Tirzepatide (Zepbound)\, phase na\, Psoriatic Arthritis.\nStudy
 : Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthriti
 s\nEstimated primary completion: February 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07443956
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07387796-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Tirzepatide (Zepbound): Phase na readout est. (NCT07387796)
DESCRIPTION:Tirzepatide (Zepbound)\, phase na\, Obesity.\nStudy: Clinical a
 nd Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reini
 tiation\nEstimated primary completion: February 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07387796
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07096908-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20280225
DTEND;VALUE=DATE:20280226
SUMMARY:Tirzepatide (Zepbound): Phase 4 readout est. (NCT07096908)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 4\, Obesity.\nStudy: Tirzepatide
  Use in People With Obesity and Type 1 Diabetes\nEstimated primary complet
 ion: 25 February 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/tirzepatide-zepbound#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07096908
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06937086-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT06937086)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: Mirikizumab
  Administered at the Same Time as Tirzepatide in Adult Participants With M
 oderately to Severely Active Ulcerative Colitis and Obesity or Overweight:
  Phase 3b Study\nEstimated primary completion: April 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06937086
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06937099-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT06937099)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Crohn's Disease.\nStudy: Mir
 ikizumab and Tirzepatide Administered in Adult Participants With Moderatel
 y to Severely Active Crohn's Disease and Obesity or Overweight\nEstimated 
 primary completion: May 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/tirzepatide-zepbound#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06937099
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06857942-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Tirzepatide (Zepbound): Phase 4 readout est. (NCT06857942)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 4\, Obesity.\nStudy: A Study to 
 Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiat
 ion of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaq
 ue PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-Ps
 O)\nEstimated primary completion: May 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06857942
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07633639-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Tirzepatide (Zepbound): Phase na readout est. (NCT07633639)
DESCRIPTION:Tirzepatide (Zepbound)\, phase na\, Obesity.\nStudy: GLP-1 Ther
 apy After Bariatric Surgery in Chinese Patients With Obesity\nEstimated pr
 imary completion: 1 May 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/tirzepatide-zepbound#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07633639
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05912621-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT05912621)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: Tirzepatide
 : Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With O
 verweight/Obesity\nEstimated primary completion: June 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05912621
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07065552-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Tirzepatide (Zepbound): Phase 1 readout est. (NCT07065552)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 1\, Obesity.\nStudy: Tirzepatide
  in Obesity-Driven Endometrial Cancer\nEstimated primary completion: July 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zep
 bound#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07065552
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07747805-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20280815
DTEND;VALUE=DATE:20280816
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT07747805)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: GLP-1 Agoni
 sts for Lung Function Improvement and Muscle Restoration in COPD\nEstimate
 d primary completion: 15 August 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07747805
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07868354-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20280907
DTEND;VALUE=DATE:20280908
SUMMARY:Tirzepatide (Zepbound): Phase 1 readout est. (NCT07868354)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 1\, Obesity.\nStudy: A Research 
 Study Investigating How Adults With Overweight or Obesity\, With or Withou
 t Type 2 Diabetes\, Tolerate Switching to a New Treatment (Zenagamtide) Fr
 om Their Current Tirzepatide Medication\nEstimated primary completion: 7 S
 eptember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tirzep
 atide-zepbound#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07868354
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07589322-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Tirzepatide (Zepbound): Phase na readout est. (NCT07589322)
DESCRIPTION:Tirzepatide (Zepbound)\, phase na\, Obesity.\nStudy: Comparativ
 e Observation of Metabolic and Pharmacologic Adipose Remodeling With Enhan
 ced Incretin AgonisTs\nEstimated primary completion: 30 September 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075893
 22
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06180616-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT06180616)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: Tirzepatide
  for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity
 \nEstimated primary completion: December 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06180616
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07829198-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT07829198)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: Efficacy of
  Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss
  After Bariatric Surgery: A Randomized\, Double-Blind\, Placebo-Controlled
  Clinical Trial\nEstimated primary completion: December 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07829198
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07326111-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tirzepatide (Zepbound): Phase 4 readout est. (NCT07326111)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 4\, Obesity.\nStudy: A Clincial 
 Study Testing Tirzepatide on Reproductive Function and Metabolic Health in
  Women With PCOS Who Are Overweight or Obese\nEstimated primary completion
 : December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tirz
 epatide-zepbound#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07326111
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07846865-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Tirzepatide (Zepbound): Phase 2/3 readout est. (NCT07846865)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2/3\, Obesity.\nStudy: Tirzepati
 de Versus Positive Airway Pressure for the Treatment of Obstructive Sleep 
 Apnoea\nEstimated primary completion: 1 December 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07846865
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07078838-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT07078838)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: Tirzepatide
  in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade
  1 Endometrial Cancer\nEstimated primary completion: March 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07078838
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07554638-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Tirzepatide (Zepbound): Phase 4 readout est. (NCT07554638)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 4\, Obesity.\nStudy: Incretin Th
 erapies in Obesity-related HFpEF\nEstimated primary completion: April 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepboun
 d#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 554638
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07574723-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20290515
DTEND;VALUE=DATE:20290516
SUMMARY:Tirzepatide (Zepbound): Phase na readout est. (NCT07574723)
DESCRIPTION:Tirzepatide (Zepbound)\, phase na\, Obesity.\nStudy: Tirzepatid
 e Titration to Reduce Side Effects in Individuals With Obesity\nEstimated 
 primary completion: 15 May 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/tirzepatide-zepbound#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07574723
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06582875-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT06582875)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: Glucagon-Li
 ke Peptide-1 Receptor Agonist in ADPKD\nEstimated primary completion: 30 J
 une 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide
 -zepbound#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06582875
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07247084-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Tirzepatide (Zepbound): Phase 4 readout est. (NCT07247084)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 4\, Obesity.\nStudy: A Study of 
 Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participan
 ts With Obesity and Without Diabetes (SURMOUNT-REAL UK)\nEstimated primary
  completion: July 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/tirzepatide-zepbound#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07247084
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07630454-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Tirzepatide (Zepbound): Phase 4 readout est. (NCT07630454)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 4\, Obesity.\nStudy: Tirzepatide
  on Atrial Fibrillation Recurrence After Catheter Ablation in Patients Wit
 h Obesity and HFpEF\nEstimated primary completion: 1 August 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07630454
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06885736-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20290830
DTEND;VALUE=DATE:20290831
SUMMARY:Tirzepatide (Zepbound): Phase na readout est. (NCT06885736)
DESCRIPTION:Tirzepatide (Zepbound)\, phase na\, Obesity.\nStudy: LEAN Mass 
 Preservation With Resistance Exercise and Protein During Semaglutide/Tirze
 patide Therapy\nEstimated primary completion: 30 August 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06885736
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06517212-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT06517212)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: Tirzepatide
  Weight Loss for MRD+ Early Breast Cancer\nEstimated primary completion: 3
 1 August 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tirzep
 atide-zepbound#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06517212
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07715929-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20290901
DTEND;VALUE=DATE:20290902
SUMMARY:Tirzepatide (Zepbound): Phase 4 readout est. (NCT07715929)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 4\, Obesity.\nStudy: Effect of T
 irzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in
  Obese Patients\nEstimated primary completion: 1 September 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07715929
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07881432-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT07881432)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: A Study of 
 EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes\nEstim
 ated primary completion: October 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07881432
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07881458-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT07881458)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: A Study of 
 EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabe
 tes\nEstimated primary completion: October 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07881458
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07349641-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT07349641)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: A Study of 
 Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Devic
 e to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer\nEstimat
 ed primary completion: 31 October 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07349641
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07817875-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Tirzepatide (Zepbound): Phase 3 readout est. (NCT07817875)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 3\, Obesity.\nStudy: Efficacy\, 
 Safety\, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versu
 s Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Hav
 e Obesity (ADVANCE-SURMOUNT-KIDS)\nEstimated primary completion: December 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zep
 bound#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07817875
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07900074-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Tirzepatide (Zepbound): Phase 4 readout est. (NCT07900074)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 4\, Obesity.\nStudy: Mechanisms 
 of Weight Loss: Tirzepatide vs Semaglutide\nEstimated primary completion: 
 31 December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tir
 zepatide-zepbound#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07900074
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07693608-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20300201
DTEND;VALUE=DATE:20300202
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT07693608)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: An Open-Lab
 el Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder\nEsti
 mated primary completion: 1 February 2030. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07693608
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07874828-11052@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20341231
DTEND;VALUE=DATE:20350101
SUMMARY:Tirzepatide (Zepbound): Phase 2 readout est. (NCT07874828)
DESCRIPTION:Tirzepatide (Zepbound)\, phase 2\, Obesity.\nStudy: PROACT AYA:
  Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide 
 In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm\, Si
 ngle-Center Feasibility Study\nEstimated primary completion: 31 December 2
 034. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-zepb
 ound#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07874828
URL:https://assetmemo.bio/drug/tirzepatide-zepbound#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
